Drug Profile
Brivaracetam - UCB Pharma
Alternative Names: BRIVIACT; BRIVIACT CV; BRIVLERA; RIKELTA; UCB-34714Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator UCB
- Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
- Mechanism of Action Sodium channel antagonists; SV2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Epilepsy
- Preregistration Partial epilepsies
- Phase III Absence epilepsy
- Discontinued Myoclonic epilepsies; Postherpetic neuralgia
Most Recent Events
- 18 Mar 2024 UCB Biopharma plans a phase III trial for Absence epilepsy (In children, In adolescents, In adults, In the elderly) in April 2024 (PO) (NCT06315322)
- 15 Mar 2024 UCB Biopharma plans a phase I trial (In volunteers) (PO), in April 2024 (NCT06312566)
- 31 Jul 2023 Preregistration for Partial epilepsies (In adults, Adjunctive treatment, In adolescents) in Japan (IV)